A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
Background In lymphoid malignancies, the introduction of chimeric antigen receptor T (CAR-T) cells and bispecific antibodies (bsAbs) has achieved remarkable clinical success. However, such immunotherapeutic strategies are not yet established for acute myeloid leukemia (AML), the most common form of...
Saved in:
| Main Authors: | Melanie Märklin, Gundram Jung, Jonas S Heitmann, Joseph Kauer, Helmut R Salih, Stefanie Mueller, Bochong Li, Latifa Zekri, Naveen K Mehta, Martin Pfluegler, Kristan Meetze, Isabelle Sindel, Fabian Vogt, Lukas Osburg, Hans-Jörg Bühring, Sebastian Hörner, Patrick A Baeuerle, Jennifer S Michaelson |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-03-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/3/e003882.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
by: Hans-Georg Rammensee, et al.
Published: (2020-05-01) -
T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer
by: S. M. Greiner, et al.
Published: (2025-07-01) -
Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
by: Melanie Märklin, et al.
Published: (2022-02-01) -
CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
by: Agapitos Patakas, et al.
Published: (2023-08-01) -
Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
by: Jing Wang, et al.
Published: (2021-10-01)